Skip to main content
. Author manuscript; available in PMC: 2023 Feb 1.
Published in final edited form as: Biomaterials. 2022 Jan 18;281:121374. doi: 10.1016/j.biomaterials.2022.121374

Figure 7: NanoLymph induced immunomodulation.

Figure 7:

(A) DC recruitment at NanoLymph (B) Activated DCs in NanoLymph (C) DC migration to adjacent inguinal lymph node. (D) OVA+ DC localized at draining LN. (E) CD4+ T cell in LN. (F) Proportion of OVA tetramer+ CD4+ T cell in LN. (G) CD8+ T cell in LN. (H) Proportion of Ova tetramer+ CD8+ T cell in LN. Control NanoLymph in gray, Antigen only in orange, Drug only in green, Drug antigen combination in blue. All endpoints evaluated 14 days after transQ loading. Graphs are plotted as mean ± SD. Statistical significance determined via one-way ANOVA.